Introduction
Von Willebrand factor (VWF) is a multimeric glycoprotein present in blood plasma, the subendothelial matrix as well as in storage granules in platelets (a-granules) and in endothelial cells (Weibel-Palade bodies, WPBs) [1] . The recently updated architecture of VWF distinguishes four different domains that are arranged in the following order: D1-D2-D'-D3-A1-A2-A3-D4-C1-C2-C3-C4-C5-C6-CK. Within this structure, the D1-D2 domains represent the propeptide, while the D'-CK portion represents the mature VWF subunit (Fig. 1 ) [2] . Upon vascular injury, VWF does what it has been designed to do best, that is, mediates the anchoring of platelets to the subendothelium, leading to the formation of a platelet plug and subsequent arrest of bleeding. A number of reviews have extensively described the mechanisms involved, and no further description will be given here [3, 4] . However, for the past 25 years and with the availability of the first murine model deficient in VWF, evidence has emerged that VWF may be involved in different aspects of vascular biology to a greater extent than originally thought (for review see [5] ). Examples thereof include the role of VWF as a negative regular of angiogenesis [6] and the ability of VWF to modulate apoptosis of tumor cells [7, 8] . Relevant to this review, VWF has also been linked to inflammation. Here, we will discuss our current understanding of the different connections, direct or indirect, between VWF and inflammatory processes.
Part 1: VWF as a marker of inflammation
The endothelium occupies a strategic position at the interface between blood and tissues and, as such, it directs the recruitment of leukocytes to inflamed areas [9] . In order to do so, endothelial cells react very rapidly to inflammatory stimuli by changing their phenotype to support the inflammatory response. In reaction to the inflammatory stimulus, endothelial cells release the content of their storage organelles, the WPBs [10] . As VWF is the main cargo of WPBs, the exocytosis of these organelles results in a massive release of VWF in the extracellular milieu, making VWF an acute phase response protein (Fig. 2) .
Indeed, an association between inflammation and increased VWF levels was already described in the 1970s [11] . The increase in VWF is predominantly endothelial cell dependent, while the contribution of platelets is limited. First, the VWF content in platelets is relatively low: 0.05-0.1 U/3 9 10 8 platelets [12] . Second, platelet VWF is selectively released upon platelet activation. Thus, substantial platelet activation would be needed to significantly participate to increased VWF levels upon inflammation.
Rather than listing all the inflammation-related pathologies in which elevation of VWF has been reported [13] , it is more relevant to assess whether measuring VWF is of clinical value, both from a diagnostic point of view and as a predictor of disease severity. In acute systemic inflammation disorders such as sepsis, acute respiratory distress syndrome or systemic inflammatory response syndrome, there is a large amount of literature trying to ascertain whether levels of VWF might be of interest to assess disease severity and outcome. The data are far from consistent. For example, despite some studies reporting that patients with the highest levels of VWF have the lowest chances of survival, such results have failed to be confirmed in other studies [14, 15] . One possible explanation for these inconsistencies may be due to the variation in the selection of confounding variables used when building regression models. Some confounding variables (e.g., obesity) may themselves affect the disease (e.g., acute respiratory distress syndrome) that VWF is trying to predict, but are not always adjusted for.
A further issue is that elevated VWF levels are not specific for an inflammatory acute phase response, but may also be regarded as an indicator of vascular dysfunction. To distinguish between an acute and a chronic endothelial perturbation, it has been proposed that both VWF and VWF propeptide (VWFpp) levels are measured [16] [17] [18] [19] . Both proteins are secreted in equal molar concentrations from endothelial cells, but have different steady state plasma concentrations due to discordant half-lives [16] . Changes in the VWFpp/VWF ratio may thus provide information on the endothelial status. For instance, van Mourik and colleagues demonstrated that both VWF and propeptide levels are increased during an acute response of the endothelium (septicemia). In contrast, VWFpp levels are only marginally increased during a more chronic stimulation (e.g., diabetes mellitus), despite elevated VWF levels [19] .
In a further effort to use VWF as a clinical marker in inflammation, Hyseni and collaborators have measured plasma concentrations of active VWF in a cohort of 275 patients with systemic inflammatory response syndrome [20] . Active VWF corresponds to VWF that is in its platelet glycoprotein Ib (GpIb)-binding conformation, a molecular form that is normally absent in healthy plasma but that is present in various pathological situations [21] . Interestingly, the authors reported that patients with high active VWF levels on admission have a 2-fold higher mortality rate. In contrast, despite strongly elevated VWF levels, no prediction of mortality could be obtained based on total VWF [20] .
Part 2: The indirect role of VWF in inflammation
Animal models of von Willebrand disease (VWD) have allowed a more targeted approach to study existing links between VWF and inflammation. However, the original animal model (i.e., pigs deficient for VWF) that was used to investigate the role of VWF in conditions of chronic inflammation (e.g., atherosclerosis) has raised more questions than answers [22] . The engineering of a mouse model of severe VWD was therefore instrumental in furthering our understanding of potential physiological functions of VWF beyond hemostasis [23] . When these mice became available, searching for a role for VWF in inflammation was not a priority. Consequently, evidence of an altered inflammatory response in the early phases of inflammation was serendipitous rather than originating from a strong working hypothesis. Indeed, the primary goal was to develop an in vivo thrombosis model in the arterioles of the mesentery using intravital microscopy. Interestingly, in all the venules located adjacent to the arterioles of interest, we detected no (or very little) leukocyte rolling in VWF-deficient mice as compared to wildtype mice. As this work was performed in the laboratory of Denisa Wagner (who, a few years previously, had published the impaired leukocyte rolling in P-selectin-deficient mice [24] ), it raised much interest and initiated the more in-depth analysis of VWF and inflammation. This study led to the conclusion that VWF is crucial for the formation of WPBs. As such storage organelles cannot be formed in the absence of VWF, complete VWF deficiency results in a defect in the expression of P-selectin at the surface of activated endothelial cells (Fig. 3 ) [25] . This translated into strongly decreased leukocyte rolling and defective leukocyte recruitment in two acute models of inflammation, a wound healing experiment and a cytokine-induced meningitis model [25] . The expression defect of P-selectin in the absence of VWF was only observed in conditions where a rapid secretion of WPBs was induced. Sustained inflammation, in atherosclerosis for instance, led to P-selectin expression at the endothelial surface even in the absence of VWF, probably resulting from new synthesis of the protein and direct membrane exposition [26] .
Despite the presence of P-selectin, atherosclerotic streaks in VWF-deficient mice are characterized by a 40% reduction in the number of recruited monocytes, suggesting that VWF may influence leukocyte recruitment beyond P-selectin [26] . In addition, P-selectin is not the only WPB resident protein involved in inflammatory processes.
Other proteins, both pro-inflammatory (Interleukin-8, Eotaxin-3) and anti-inflammatory (Factor H) have been reported to be present in these organelles [27, 28] . Whether VWF regulates the targeting of these various proteins as it does for P-selectin and what happens to these effectors when WPBs are absent is currently unknown. What we do know is that WPBs display remarkable plasticity and that although VWF is key to their biogenesis and size determination [29] , not all aspects of WPBs biology are VWF related. Indeed, depending on the secretory stimulus, WPBs are capable of a selective release of their cargo, either small vs. large molecules [30] or even VWF vs. P-selectin [31] , demonstrating that WBPs exocytosis is not absolutely linked to VWF secretion. This plasticity . Both pro-and anti-inflammatory mediators are present and will participate in the inflammatory response. One of these mediators is P-selectin which will be exposed to the endothelial surface to serve as a receptor for leukocyte rolling. In the absence of VWF (right panel), no WPBs are formed and as a consequence P-selectin is unable to efficiently accumulate at the endothelial surface, impairing leukocyte rolling. How VWF deficiency affects release of other WPBs resident proteins such as IL-8, Eotaxin-3 and factor H remains to be determined.
probably reflects endothelial cell heterogeneity throughout the vascular tree and the multiple regulatory roles of these cells. It also leaves plenty of room for differential VWF involvement in WPB-mediated regulation of inflammation.
Aside from its crucial role in WPB formation, VWF can also indirectly affect inflammation through other means. For instance, VWF remains in complex following its secretion with several WPBs resident proteins that are known to contribute to the inflammatory process, like galectins, angiopoietin-2, and osteoprotegerin [5] . As such, VWF may change the inflammatory potential of these proteins either positively or negatively. Another indirect link between VWF and inflammation relates to factor VIII. Indeed, factor VIII is a procoagulant cofactor that enhances thrombin generation, a process that promotes inflammation. As its chaperone, VWF plays a crucial role in maintaining normal factor VIII levels.
Part 3: The direct role of VWF in inflammation
VWF-dependent leukocyte recruitment in in vivo models for inflammation Apart from being a marker for inflammatory responses and also responsible for the formation of endothelial storage organelles, there is also evidence that VWF may serve as a more direct effector of inflammation. This evidence is primarily based on data obtained from animal models. For instance, VWF-deficient mice have been used to investigate the effect of VWF on leukocyte recruitment in models for cutaneous inflammation [32] . In two distinct models (immune complex-induced vasculitis [ICV] and irritative contact dermatitis [ICD]), a significant reduction in the number of recruited leukocytes (50-65%) was observed in VWF-deficient mice compared to wild-type mice. Thus, similar to what had been previously reported for atherosclerosis, cutaneous inflammation models also revealed a strong correlation between the presence of VWF and the extent of leukocyte recruitment to sites of inflammation. However, based on these data using VWF-deficient mice alone, it can still not be excluded (as described in the previous paragraph) that this effect originates from an absence of WPBs in the endothelial cells. To overcome this limitation, Hillgruber and colleagues have also assessed the inflammatory response in wild-type mice in the presence of polyclonal anti-VWF antibodies [32] . By doing so, they observed that the presence of anti-VWF antibodies was efficient in significantly reducing leukocyte recruitment by about 50%, similar to that of VWF-deficient mice. Anti-VWF antibodies have been used in a model for thioglycollateinduced peritonitis as well, revealing that antibodymediated blocking of VWF resulted in a profound reduction in the transmigration of leukocytes into the peritoneum [33] .
The contribution of VWF to leukocyte recruitment and cerebral inflammation has further been addressed in an experimental model for intracerebral hemorrhage (ICH) [34] . In this model, autologous blood is injected in the striatum of the mouse brain, generating a hematoma that in turn provokes an inflammatory response. Rather than using anti-VWF antibodies, the authors infused human VWF, and the presence of increased VWF concentrations was associated with increased numbers of microglia and neutrophils in the inflamed area, irrespective of whether VWF was given intraventricularly or intravenously [34] . Taken together, these various experimental models of inflammation all point to a direct role of VWF in the inflammatory response by contributing to the recruitment of leukocytes to sites of inflammation.
VWF-mediated changes in vascular permeability
Vascular inflammation not only results in exaggerated leukocyte recruitment, but is also associated with increased vascular permeability, due to weakening of the endothelial junctions [35] . In that regard, a common point in the studies described in the previous paragraph was that VWF deficiency or antibody-mediated inhibition of VWF was associated with a significant decrease in vascular permeability (Fig. 4) [32] [33] [34] , whereas the addition of extra VWF resulted in increased vascular permeability in the experimental ICH-model [34] . Permeability has been differentially measured via the use of Evan's blue leakage, skin biopsy weight, or brain water content. The possibility for VWF to be involved in the regulation of vascular permeability had previously been shown in studies that specifically addressed bloodbrain barrier (BBB)-permeability using different experimental models [36, 37] . However, conflicting results were obtained according to the models that were used. Using two models normally associated with increased BBB permeability, hypoxia/reoxygenation or pilocarpine-induced status epilepticus, BBB permeability was found to be better preserved in VWFdeficient mice compared to control mice [37] , similar to that reported for the inflammation models above. Again, this effect was VWF specific, as similar results were obtained using aptamer-mediated inhibition of VWF. In contrast, VWF deficiency was reported to result in a marked increase in BBB permeability in an experimental model for allergic encephalomyelitis, resulting in an increased infiltration of lymphocytes and monocytes [36] . Finally, the extent of vascular permeability was shown to be fully independent of VWF in a model of zymosaninduced inflammation [38] . Thus, the extent of how VWF modulates vascular permeability may depend on the experimental model that is applied, although the majority of models point to VWF increasing vascular permeability. Interestingly, preservation of the BBB permeability in VWF-deficient mice was not necessary associated with a better outcome: Indeed, in contrast to wild-type mice, the large majority of whom survived, all VWF-deficient mice died during the course of the disease [37] . The mechanism by which VWF modulates endothelial permeability remains to be determined. A starting point in this regard is the observation that VWF may regulate the expression of the endothelial tight-junction protein claudin-5 [37] . Another possibility is that VWF modulates the endothelial barrier function via interaction with specific receptors, such as a V b3 or LRP1. VWF is a ligand for these receptors, which both have been linked to changes in vascular permeability during inflammation [39, 40] .
Direct interactions between VWF and leukocytes
In search for the mechanisms involved in VWF-dependent leukocyte recruitment, it was noted that the increased VWF-dependent vascular permeability observed in the ICD-, ICV-, and ICH-models was accompanied by an increased accumulation of VWF in the extravascular space, as if VWF had been penetrating to the inflammatory sites (Fig. 4) [32, 34] . Whether this extravascular accumulation contains extravasated plasma VWF, VWF that is directly released from endothelial cells to the basal subendothelial matrix, or both, is yet unclear. Irrespective of its origin, it is interesting to note that increased infiltration of VWF in the subendothelial regions had already been reported in several studies that examined the vascular injury response [41] [42] [43] , suggesting that extravascular accumulation of VWF represents a common process under certain pathological conditions. Importantly, extravascular accumulation of VWF has not only been observed in animal models, but also in skin biopsies taken from patients suffering from ICV [32] .
Combining the increased vascular permeability and the extravascular presence of VWF, together leading to enhanced leukocyte recruitment, it becomes tempting to speculate that VWF possesses chemo-attractant capacities. Although this remains to be demonstrated, we at least know that VWF is able to directly interact with leukocytes. In an elegant study by Koivunen and colleagues, a tri-peptide motif (Leu-Leu-Gly) was identified that interfered with b2-integrin dependent leukocyte adhesion [44] . Interestingly, this tri-peptide motif is not only present in the known b2-integrin counter-receptor ICAM-1, but also occurs twice in the VWF protein sequence (in the D3 domain, and within the inter-A1-A2 domain region). Prompted by this finding, the authors indeed observed adhesion of phorbol ester stimulated THP-1 cells to immobilized VWF under static conditions [44] , providing the first data showing that VWF can act as an adhesive surface for leukocytes (Fig. 4) . We were able to confirm the adhesion of monocytic cell lines (THP-1 and U937-cells) to VWF under static conditions. Importantly, leukocyte adhesion was not limited to monocytic cells lines. Blood-borne monocytes and polymorphonuclear cells (PMNs) also proved able to adhere to VWF as efficiently as to fibrinogen [45] . When assessed under conditions of flow, PMNs were observed to make predominantly short-lasting contacts (< 3 s) when perfused over a VWF-coated surface [45] . In contrast, the number of firmly adhered cells was increased 10-fold when phorbol ester-activated PMNs were perfused, indicating that the adhesion process involves an initial step to decelerate leukocytes, and a secondary step that mediates firm adhesion. Of note, elimination of the Leu-Leu-Gly sequences (each of them alone, or in tandem) in VWF left leukocyte adhesion unaffected [45] , suggesting that these tri-peptide motifs play a minor role, if any, in the interaction between VWF and b2-integrins expressed on bloodborne leukocytes.
Leukocyte receptors for VWF
The multistep mechanism characterizing rolling and adhesion of leukocytes to VWF points to the involvement of different leukocyte receptors in the interaction with VWF. Indeed, we were able to demonstrate that VWF is able to interact with two distinct leukocyte receptors: PSGL-1 and the various b2-integrins (aMb2, aLb2 and aXb2) [45] . Inhibition of PSGL-1 reduced rolling over VWF, whereas inhibition of b2-integrins interfered with stable adhesion. As such, leukocyte interactions with VWF mimic those with endothelial cells, where PSGL-1/P-selectin interactions determine rolling and b2-integrin/ICAM-1 interactions contribute to stable adhesion [46] .
To identify binding sites for PSGL-1 and b2-integrins, we analyzed their interaction with recombinant VWF fragments. b2-integrins were found to bind to two distinct fragments, encompassing the D'-D3 and A1-A2-A3 domains, pointing to the presence of at least two separate interactive sites for b2-integrins [45] . As for PSGL1, we observed that this protein interacted with the VWF A1-A2-A3 fragment (Fig. 1) . As deletion of the A2-or A3-domain in VWF had no effect on PSGL-1 binding, it would appear that the A1 domain contains a binding site for PSGL-1 [45] . Considering the structural similarities between PSGL-1 and GpIba (the main ligand for VWF on platelets), the involvement of the VWF A1 domain is not very surprising [46] . A second point of convergence between VWF interacting with GpIba and PSGL-1 is that VWF needs to be in its active conformation. This would imply that when VWF is constitutively active (like in VWD-type 2B), its inflammatory activity might be increased. We tested this possibility in our knock-in mouse model for VWD-type 2B, which faithfully resembles the clinical phenotype of the disorder [47] . By applying the ICV-model (here called reverse passive Arthus reaction), we could observe an exaggerated vascular permeability in the VWD-type 2B mice (both hetero-and homozygous) as manifested by an increased presence of hemoglobin in the inflamed tissue [47] . This increased permeability was associated with an increased exfiltration of leukocytes. Thus, VWF in its active conformation indeed appears to promote the inflammatory response. This result is relevant in light of the observation reported in part 1 of this review that active VWF may be a better marker than VWF to assess disease severity in patients with systemic inflammatory response syndrome [20] . Apart from PSGL-1 and b2-integrins, it is also worth mentioning that VWF may use its RGD-motif (residues 2507-2509 in the C4-domain; Fig. 1 ) to interact with a V b 3 -integrin [44] , which is present on most leukocytes. In addition, leukocytes further contain other receptors that have been identified to interact with VWF, such as Siglecs and LRP1 [48, 49] . Whether these receptors are able to contribute to the process of leukocyte adhesion requires further investigation.
ADAMTS-13 as regulator of VWF inflammatory activity
The presence of active VWF is not limited to VWD-type 2B. As already mentioned, active VWF is increased in several disorders characterized by an inflammatory response [21] . Another condition that is characterized by the presence of active VWF is thrombotic thrombocytopenic purpura (TTP). This disorder is due to the functional absence of ADAMTS-13, a metalloprotease that is able to cleave VWF in its A2 domain [50] . As a consequence, the ultralarge VWF multimers that are released by endothelial cells are not converted into smaller fragments. Importantly, these very large multimers adopt an active conformation [51] , and thus form VWF/platelet aggregates that occlude the microvasculature. In addition, VWF that is released from WPBs upon endothelial stimulation remains bound to the cellular surface, and long platelet-decorated strings are formed [52, 53] . Interestingly, platelet-decorated strings that are being formed in ADAMTS-13-deficient conditions have been found to act as an adhesive surface for leukocytes (Fig. 5) [54, 55] . Furthermore, ADAMTS-13-deficiency was associated with increased leukocyte recruitment in models for skin excision and thioglycollate-induced peritonitis [55] . This ADAMTS-13-mediated effect was only observed in VWF-expressing but not in VWF-deficient mice, indicating that it fully relies on the presence of VWF. Apparently, ADAMTS-13 mediates its anti-inflammatory effect by preventing the persistence of ultralarge VWF multimers. The possibility that ADAMTS-13 reduces VWFdependent exaggeration of the inflammatory response has also been confirmed in models for acute ischemic stroke [56] [57] [58] [59] , acute myocardial ischemia/reperfusion injury [60] , and leukocyte recruitment to atherosclerotic plaques [61, 62] .
Recently, it has been highlighted that the anti-inflammatory actions of ADAMTS-13 via proteolysis of VWF may be counteracted by small peptides released from neutrophils: human neutrophil peptides (HNPs, also known as a-defensins) [63] . These peptides resemble part of the ADAMTS-13 protein sequence (in particular a RRY motif located in the ADAMTS-13 spacer domain) and compete with ADAMTS-13 for binding to VWF A2 domain, where the cleavage site for ADAMTS-13 is located. Levels of HNPs in plasmas from TTP patients are increased, which may contribute to the increased susceptibility for respiratory, gastrointestinal, and central line infections that often In addition, platelet-decorated VWF strings are able to mediate rolling and adhesion of leukocytes also under high shear stress, as part of the platelets are activated and express P-selectin. Moreover, activated platelets may release their content, which contains pro-and antiinflammatory agents that can modulate the inflammatory response. Under normal conditions, the VWF-cleaving protease ADAMTS-13 degrades the UL-VWF multimers, preventing excessive leukocyte recruitment. In contrast, some pathological conditions are associated with insufficient ADAMTS-13 activity, which may amplify the inflammatory response, leading to increased disease severity and poor outcome.
precedes an acute episode of TTP [63] . Also, the pro-inflammatory cytokine interleukin-6, which is released upon the inflammatory response, has been reported to limit ADAMTS-13 function [64] . As described in part 1 of this review, several inflammatory conditions are associated with increased VWF antigen levels. Interestingly, there exists an inverse relationship between plasma levels of VWF and ADAMTS-13 [65] , possibly because of increased consumption and/or because the VWF-bound ADAMTS-13 fraction (which is cleared more rapidly than free ADAMTS-13) will increase when VWF levels increase. In light of the relationship between VWF, ADAMTS-13, and inflammation, several studies have been performed to investigate whether an imbalance between VWF and ADAMTS-13 could contribute to the severity of the inflammatory response [66, 67] . To cite a few, Martin and coworkers observed a strong negative correlation between ADAMTS-13 activity and APACHE II score and number of organ failures (ODIN score) in patients with severe sepsis [68] . Also, lower ADAMTS-13 correlated with reduced survival in these patients [68] . High VWF levels and low ADAMTS-13 levels have also been reported in sepsis patients in a study by KremerHovinga and colleagues, but no association between this disturbed ADAMTS-13/VWF ratio and survival could be observed [69] . In another study, Bockmeyer and colleagues found that reduced ADAMTS-13 levels were associated with elevated levels of inflammatory markers (interleukin-6 and procalcitonin) in patients with systemic inflammatory response syndrome and sepsis, who were held at the intensive care unit [70] . They observed that decreased ADAMTS-13 levels in combination with the presence of ultralarge VWF multimers resulted in an increased disease severity, as illustrated by increased severity of organ dysfunction (SOFA)-score and the increased mortality [70] . Finally, decreased ADAMTS-13 activity and increased VWF levels were further reported to be associated with systemic inflammation in patients with advanced cirrhosis [71] . Again, the lowest transplant-free survival and highest mortality were observed in patients with the lowest ADAMTS-13/VWF ratio [71] .
Taken together, there is accumulating evidence from both animal models and the analysis of patients with severe inflammatory responses that ADAMTS-13 plays a crucial role in downregulating the proinflammatory potential of VWF (Figs. 2 and 5) . In this regard, therapeutic approaches aiming to restore ADAMTS-13 levels may be worth considering [67] .
The VWF -GpIba axis
The mechanism by which VWF affects inflammation may be variable. Above, we have seen that VWF is able to interact directly with leukocytes. However, there are also indications that VWF attracts leukocytes in an indirect platelet-dependent manner. When ultralarge VWF strings are released from endothelial cells, they rapidly recruit platelets via interactions with the platelet receptor GpIba. Bernardo and colleagues have observed that platelets adhered to ultralarge VWF strings at the endothelial surface are able to bind beads coated with an anti-P-selectin antibody or with or PAC-1 antibodies, suggesting that at least a portion of these adhered platelets are activated [54] . As a consequence of this P-selectin exposure, leukocyte rolling was detected even under conditions of high shear rates [54] . Thus, whereas VWF is likely to interact with leukocytes under venous shear conditions, it probably requires complex formation with platelets to do so under arterial shear conditions.
The importance of platelet recruitment on freshly released VWF for leukocyte recruitment in vivo was confirmed by Petri and colleagues, who found that leukocyte exfiltration in a thioglycollate-induced peritonitis model could be blocked via platelet depletion or using functionblocking anti-GpIba antibodies [33] . However, these authors found that leukocyte rolling was P-selectin independent and as mentioned earlier in the review, leukocyte capture would appear to be facilitated through modifications of the vascular permeability [33] . Further evidence for a role of GpIba came from studies using genetic deficiency or peptide-mediated inhibition of GpIba in mice, showing that lack of GpIba was associated with reduced systematic inflammation in various models for sepsis [72, 73] .
It should be noted that activation of platelets via the VWF/GpIba axis not only results in exposure of P-selectin (which can potentially mediate leukocyte rolling), but also in the release of several pro-and anti-inflammatory mediators [74] . Moreover, it may result in the release of platelet VWF, which in itself has been shown to be capable of enhancing leukocyte recruitment in a stroke model [57] . Together, it seems that regulation of the VWFGpIba axis is essential to prevent exaggerated inflammatory responses.
VWF and neutrophil extracellular traps
Recently, another link between VWF and inflammation was uncovered. Rather than being another way in which VWF plays a direct role in inflammatory processes, certain inflammatory reactions have now been shown to highjack the pro-thrombotic properties of VWF to induce the now termed immuno-thrombosis. During inflammatory responses, neutrophils may release their nuclear material (including DNA and histones), allowing the formation of neutrophil extracellular traps (NETs) [75, 76] . These NETs are particularly efficient in trapping pathogens, but also VWF, which may contribute to the pathogenesis of deep vein thrombosis [77] . Gr€ assle and colleagues found that VWF uses its A1 domain for binding to the DNA-component of these NETs and report that incorporation in these NETs does not alter VWF degradation by ADAMTS-13 [78] . An older study also demonstrated that the VWF A1 domain contains an interactive site for histones, a component that is abundantly present in the NETs [79] . Histones may thus promote the inclusion of VWF in these NETs. Interestingly, VWF that is included in the NETs was found to promote leukocyte recruitment, thereby exacerbating ischemia/reperfusion injury [80] . As such, the NETs (although originally designed to limit spreading of infectious pathogens) may indirectly contribute to the exaggerated inflammatory response that may occur upon their uncontrolled release.
Conclusion
The multifunctional capacities of VWF have now been outlined in a variety of scientific reports over the past 20 years [5] . As a large protein with a multiplicity of ligands, VWF can indeed be linked to some unexpected pathophysiological processes. In relation to inflammation, this is perhaps not unexpected considering its intricate links with hemostasis. Although it is well established that VWF is an acute phase response protein, its poor specificity and predictive value make it difficult to use in a reliable manner in a clinical setting [13] . Whether VWF propeptide or active VWF measurements could be more specific, represent very attractive possibilities but ones that have not been sufficiently substantiated yet. As for VWF involvement in leukocyte recruitment, we are now faced with a number of different studies all agreeing on the fact that there is indeed such a role but with many potential mechanisms at play. Whether indirectly through WBP release or directly through binding sites on the VWF structure, regulation of vascular permeability, or via platelets, the role of VWF in inflammation is slowly coming into focus. The complete picture is not yet totally clear and pieces of the puzzle remain to be placed. However, it is important to bear in mind that our knowledge on the involvement of VWF in inflammatory processes primarily originates from experimental models using animal studies. No reports relating to patients with VWD being more susceptible to infection have been published to date. However, to the best of our knowledge, no carefully designed study has been performed capable of specifically addressing this issue. The accumulation of VWF in skin biopsies of patients suffering from immune complex-mediated vasculitis favors a role for VWF in inflammation in humans [32] . For atherosclerosis, human studies have not confirmed a role for VWF in the development of the lesions [81] . The multifactorial nature of the disease as well as the individual genetic susceptibility and the VWF replacement therapy in patients represents as many confounding variables that complicate human studies. Finally, it would appear that in inflammation, similar to hemostasis, the multimeric structure of VWF is of importance as ADAMTS-13 plays an important role in downregulating the pro-inflammatory potential of VWF.
Such studies emphasize the potential of targeting VWF to reduce inflammation as well as its downstream consequences in immuno-thrombosis.
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